# US 2024/0201132 A1 · Improved detection of hemoglobin and other compounds by electrophoresis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201132 A1
- Document ID: US20240201132A1
- Status: Published application
- Kind: A1
- Application number: 18/555,955
- Filed: 2022-04-25
- Published: 2024-06-20
- Earliest claimed: 2021-04-23
- Applicants: Hemex Health, Inc.
- Inventors: Peter GALEN; David John SAYLER; James Daren BLEDSOE; Muhammad Noman HASAN; Joshua King HOYT; Jered WIKANDER; Tyler WITTE; Alireza AVANAKI; Yiyang FEI; Anne ROCHELEAU; Umut Atakan GURKAN
- Web page: https://patentgrep.com/patent/US20240201132A1

## CPC

- G01N 27/44721: {by optical means}
- G01N 33/68: involving proteins, peptides or amino acids {(involving lipoproteins G01N33/92)}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The disclosed methods and systems use multi-spectral imaging of band data in point-of-care devices during active electrophoresis test runs to detect sensitive disease state compounds, such as hemoglobin and its variants and sub-variants. The multi-spectral imaging identifies an imaging wavelength of light that, when emitted towards the electrophoresis strip, optimizes images of the electrophoresis strip that are captured during the test. These optimized images allow for detection of the target compound, particularly at low concentrations and with low limits of detection (LoD).

## Claims

### Claim 1

A method of detecting a compound in a patient sample in a point-of-care diagnostic device, comprising:
determining absorption or fluorescence characteristics of the compound;
selecting an imaging wavelength of light based on the absorption or fluorescence characteristics;
during the active run of the electrophoresis test, causing emission of light at the imaging wavelength and at a second wavelength towards an electrophoresis strip having the patient sample;
generating an image of a band on an electrophoresis strip during an active run of an electrophoresis test;
during the active run of the electrophoresis test, determining an absorption characteristic or a fluorescence characteristic of absorbed or fluoresced light, respectively, from the imaged band on the electrophoresis strip; and
determining presence of the compound in the patient sample based on the absorption characteristic or the fluorescence characteristic of the absorbed or fluoresced light, respectively.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound has a limit of detection (LoD) in the patient sample when imaged during emission of the light at the imaging wavelength that is lower than an LoD of the compound when imaged during emission of white light or light at a wavelength other than the imaging wavelength.

### Claim 3 (depends on 1)

The method of claim 1, further comprising determining a variant type or a sub-variant type of the compound in the patient sample based on the absorption characteristic, the fluorescence characteristic, a position over time of a band indicative of the variant type or the sub-variant type of the compound, or a shape of the band.

### Claim 4 (depends on 1)

The method of claim 1, wherein selecting the imaging wavelength of light based on the absorption characteristics includes selecting a wavelength of maximum absorption or fluoresce of the compound.

### Claim 5 (depends on 1)

The method of claim 1, wherein selecting the imaging wavelength of light based on the absorption characteristics includes selecting a wavelength of maximum absorption or fluoresce of the compound of within a range of 390-430 nanometers (nm).

### Claim 6 (depends on 1)

The method of claim 1, wherein during the active run of the electrophoresis test, causing emission of light at the imaging wavelength at a first time during the active run and causing emission of light at the second wavelength at a second time during the active run.

### Claim 7 (depends on 1)

The method of claim 1, further comprising:
determining a shape of the band on the electrophoresis strip; and
quantifying the compound based on a characteristic of the shape and location of the band.

### Claim 8 (depends on 1)

The method of claim 1, further comprising:
adjusting an intensity of the emission of the light at the imaging wavelength from a first intensity to a second intensity; and
determining presence of the compound in the patient sample based on a difference between the absorption characteristic or the fluorescence characteristic of the absorbed or fluoresced light, respectively, at the first intensity and the second intensity.

### Claim 9 (depends on 1)

The method of claim 1, further comprising outputting data indicating presence of the compound in the patient sample.

### Claim 10 (depends on 1)

The method of claim 1, further comprising:
generating multiple images of the band on the electrophoresis strip during the active run of the electrophoresis test;
determining absorption characteristics or fluorescence characteristics of the absorbed or fluoresced light, respectively, from the multiple images of the band on the electrophoresis strip; and
determining presence of the compound in the patient sample based on the absorption characteristics or the fluorescence characteristics of the absorbed or fluoresced light, respectively.

### Claim 11 (depends on 10)

The method of claim 10, further comprising:
during the active run of the electrophoresis test, causing emission of white light towards the electrophoresis strip having the patient sample;
during the active run of the electrophoresis test, generating a first of the multiple images of the band on the electrophoresis strip during the emission of light at the imaging wavelength; and
generating a second of the multiple images of the band on the electrophoresis strip during the emission of white light.

### Claim 12 (depends on 11)

The method of claim 11, further comprising generating a compiled image that overlays the first of the multiple images and the second of the multiple images.

### Claim 13 (depends on 1)

The method of claim 1, wherein causing emission of light within a range of wavelengths that includes the imaging wavelength, the light emitted towards the electrophoresis strip having the patient sample, and further comprising applying a filter to the emitted light to limit the light emitted towards the band to be the light with the imaging wavelength.

### Claim 14

A system for detecting a compound in a patient sample in a point-of-care diagnostic device, comprising:
a processor configured to:
receive absorption characteristics of the compound;
select an imaging wavelength of light based on the absorption characteristics;
during the active run of the electrophoresis test, generate an instruction to cause emission of light at the imaging wavelength and at a second wavelength towards an electrophoresis strip having the patient sample;
generate an image of a band on an electrophoresis strip during an active run of an electrophoresis test;
during the active run of the electrophoresis test, determine an absorption characteristic or a fluorescence characteristic of absorbed or fluoresced light, respectively, from the imaged band on the electrophoresis strip; and
determine presence of the compound in the patient sample based on the absorption characteristic or the fluorescence characteristic of the absorbed or fluoresced light, respectively; and
an output configured to output data that indicates the presence of the compound in the patient sample.

### Claim 15 (depends on 14)

The system of claim 14, wherein the compound has a limit of detection (LoD) in the patient sample when imaged during emission of the light at the imaging wavelength that is lower than an LoD of the compound when imaged during emission of white light or light at a wavelength other than the imaging wavelength.

### Claim 16 (depends on 14)

The system of claim 14, wherein the processor is further configured to determine a variant type or sub-variant type of the compound in the patient sample based on the absorption characteristic, the fluorescence characteristic, or a shape of the band.

### Claim 17 (depends on 14)

The system of claim 14, wherein the processor is further configured to select the imaging wavelength of light based on the absorption characteristics of selecting a wavelength of maximum absorption or fluoresce of the compound.

### Claim 18 (depends on 14)

The system of claim 14, wherein the processor is further configured to select the imaging wavelength of light based on the absorption characteristics of selecting a wavelength of maximum absorption or fluoresce of the compound of in a range of 390-430 nanometers (nm).

### Claim 19 (depends on 14)

The system of claim 14, wherein the processor is further configured to generate an instruction to cause emission of light at the imaging wavelength at a first time and to generate an instruction to cause emission of light at the second wavelength at a second time.

### Claim 20 (depends on 14)

The system of claim 14, wherein the processor is further configured to:
determine a shape of the band on the electrophoresis strip; and
quantify the compound based on a characteristic of the shape of the band.

### Claim 21 (depends on 14)

The system of claim 14, wherein the processor is further configured to:
adjust an intensity of the emission of the light at the imaging wavelength from a first intensity to a second intensity; and
determine presence of the compound in the patient sample based on a difference between the absorption characteristic or the fluorescence characteristic of the absorbed or fluoresced light, respectively, at the first intensity and the second intensity.

### Claim 22 (depends on 14)

The system of claim 14, wherein the processor is further configured to output data indicating presence of the compound in the patient sample.

### Claim 23 (depends on 14)

The system of claim 14, wherein the processor is further configured to:
generate multiple images of the band on the electrophoresis strip during the active run of the electrophoresis test;
determine absorption characteristics or fluorescence characteristics of the absorbed or fluoresced light, respectively, from the multiple images of the band on the electrophoresis strip; and
determine presence of the compound in the patient sample based on the absorption characteristics or the fluorescence characteristics of the absorbed or fluoresced light, respectively.

### Claim 24 (depends on 22)

The system of claim 22, wherein the processor is further configured to:
during the active run of the electrophoresis test, cause emission of white light towards the electrophoresis strip having the patient sample;
during the active run of the electrophoresis test, generate a first of the multiple images of the band on the electrophoresis strip during the emission of light at the imaging wavelength; and
generate a second of the multiple images of the band on the electrophoresis strip during the emission of white light.

### Claim 25 (depends on 23)

The system of claim 23, wherein the processor is further configured to generate a compiled image that overlays the first of the multiple images and the second of the multiple images.

### Claim 26 (depends on 14)

The system of claim 14, wherein the processor is further configured to;
emit light within a range of wavelengths that includes the imaging wavelength, the light emitted towards the electrophoresis strip having the patient sample; and
apply a filter to the emitted light to limit the light emitted towards the band to be within the imaging wavelength.

### Claim 27 (depends on 14)

The system of claim 14, wherein the compound includes an analyte, an antibody, or a label.
